Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of fluoroquinolones in rats

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 6, 1999, Pages 1511-1515

  Delon, Annie ^b   Bouquet, Serge ^b   Huguet, Francois ^b   Brunet, Valerie ^b   Courtois, Philippe ^b   Couet, William ^a,b  

^a Faculte de Medicine et de Pharmacie   (France)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ENOXACIN; FLEROXACIN; METHYL GROUP; NORFLOXACIN; PEFLOXACIN; PIPERAZINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; EPILEPTOGENESIS; INTRAVENOUS DRUG ADMINISTRATION; LIPID SOLUBILITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SEIZURE; STRUCTURE ACTIVITY RELATION;

EID: 0033063077     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.6.1511     Document Type: Article

References (34)

1. Akahane, K., M. Sekiguchi, T. Une, and V. Osada. 1989. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with γ-aminobutyric acid receptor sites. Antimicrob. Agents Chemother. 33:1704-1708.
2. Akahane, K., Y. Tsutomi, Y. Kimura, and Y. Kitano. 1994. Levofloxacin, an optical isomer of ofloxacin, has attenuated epileptogenic activity in mice and inhibitory potency in GABA receptor binding. Chemotherapy 40:412-417.
3. A receptors in dissociated hippocampal cells of the rat. J. Neurophysiol. 66:497-504.
4. Anastasio, G. D., D. Menscer, and J. M. Little. 1988. Norfloxacin and seizures. Ann. Intern. Med. 109:169-170.
5. Arcieri, G., E. Griffith, G. Gruenwaldt, A. Heyd, B. O'Brien, N. Backer, and R. August 1987. Ciprofloxacin: an update on clinical experience. Am. J. Med. 82(Suppl. 4A):381-386.
6. Christ, W. 1990. Central nervous system toxicity of quinolones: human and animal findings. J. Antimicrob. Chemother. 26(Suppl. B):219-225.
7. Danhof, M., and G. Levy. 1984. Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J. Pharmacol. Exp. Ther. 229:44-50.
8. Dellamonica, P., and B. Dunais. 1996. Tolerability of fluoroquinolones: focus on pefloxacin. 11(Suppl.2):36-42.
9. Delon, A., F. Huguet, P. Courtois, J. M. Vierfond, S. Bouquet, and W. Couet. 1997. Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of pefloxacin and norfloxacin in rats. J. Pharmacol. Exp. Ther. 280: 983-987.
10. Delon, A., C. Pariat, P. Courtois, S. Bouquet, and W. Couet. 1998. A new approach for early assessment of the epileptogenic potential of quinolones. Antimicrob. Agents Chemother. 42:2756-2758.
11. De Sarro, G., F. Nava, G. Calapai, and A. De Sarro. 1997. Effects of some excitatory amino acid antagonists and drugs enhancing γ-aminobutyric acid neurotransmission on pefloxacin-induced seizures in DBA/2 mice. Antimicrob. Agents Chemother. 41:427-434.
12. Dodd, P. R., L. P. Davies, W. E. Watson, B. Nielsen, J. A. Dyer, L. S. Wong, and G. A. R. Johnston. 1989. Neurochemical studies on quinolone antibiotics: effect on glutamate, GABA and adenosine systems in mammalian CNS. Pharmacol. Toxicol. 64:404-411.
13. Domagala, J. M. 1994. Structure-activity and structure-side effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 33:685-706.
14. Gabrielson, J., and D. Weimer. 1997. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 2nd ed., p. 588-603. Swedish Pharmaceutical Press, Stockholm, Sweden.
15. A receptor by ciprofloxacin and biphenylacetic acid. Br. J. Pharmacol. 122:584-590.
16. Hasbun, R., and V. J. Quagliarello. 1998. Use of the quinolones in the treatment of bacterial meningitis, p. 287-301. In The quinolones, 2nd ed. Academic Press, Inc., New York, N.Y.
17. Hooper, D. C., and J. S. Wolfson. 1985. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob. Agents Chemother. 28:716-721.
18. Ichikawa, N., K. Naora, and K. Iwamoto. 1994. Comparative study of permeability into rat cerebrospinal fluid of the quinolones: dependency on their lipophilicities. Biol. Pharm. Bull. 17:152-155.
19. Imanishi, T., K. Akahane, and N. Akaike. 1995. Attenuated inhibition by levofloxacin, 1-isomer of ofloxacin, on GABA response in dissociated rat hippocampal neurons. Neurosci. Lett. 193:81-84.
20. 1. J. Pharmacol. Exp. Ther. 282:955-960.
21. Jaehde, U., M. W. E. Langemeijer, A. G. de Boer, and D. D. Breimer. 1992. Cerebrospinal fluid transport and disposition of the quinolones ciprofloxacin and pefloxacin in rats. J. Pharmacol. Exp. Ther. 263:1140-1146.
22. Jaehde, U., T. Goto, A. G. de Boer, and D. D. Breimer. 1993. Blood-brain barrier transport rate of quinolone antibacterials in cerebrovascular endothelial cell cultures. Eur. J. Pharm. Sci. 1:49-55.
23. Janknegt, R. 1986. Fluorinated quinolones: a review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy. Pharm. Weekbl. 8:1-21.
24. A receptor-mediated response and its potentiation with felbinac in Xenopus oocytes injected with mouse-brain mRNA: correlation with convulsive potency in vivo. Toxicol. Appl. Pharmacol. 145:246-254.
25. Levasseur, L. M., A. Delon, W. R. Greco, P. Faury, S. Bouquet, and W. Couet. 1998. Development of a new quantitative approach for the isobolographic assessment of the convulsant interaction between pefloxacin and theophylline in rats. Pharm. Res. 15:1069-1076.
26. Ooie, T., H. Suzuki, T. Terasaki, and Y. Sugiyama. 1996. Characterization of the transport properties of a quinolone antibiotic, fleroxacin, in rat choroid plexus. Pharm. Res. 13:523-527.
27. Ooie, T., T. Terasaki, H. Suzuki, and Y. Sugiyama. 1997. Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics. J. Pharmacol. Exp. Ther. 283:293-304.
28. Ramzan, I. M., and G. Levy. 1985. Kinetics of drug action in disease states. XIV. Effect of infusion rate on pentylentetrazol concentrations in serum, brain and cerebrospinal fluid of rats at onset of convulsions. J. Pharmacol. Exp. Ther. 234:624-628.
29. Ramzan, I. M., and G. Levy. 1986. Kinetics of drug action in disease states. XVI. Pharmacodynamics of theophylline-induced seizures in rats. J. Pharmacol. Exp. Ther. 236:708-713.
30. Scheld, W. M. 1989. Quinolone therapy for infections of the central nervous system. Rev. Infect. Dis. 11(Suppl.5):S1194-S1202.
31. Schmuck, G., A. Schurmann, and G. Schlüter. 1998. Determination of the excitatory potencies of quinolones in the central nervous system by an in vitro model. Antimicrob. Agents Chemother. 42:1831-1836.
32. Segev, S., M. Rehavi, and E. Rubinstein. 1988. Quinolones, theophylline, and diclofenac interactions with the γ-aminobutyric acid receptor. Antimicrob. Agents Chemother. 32:1624-1626.
33. Simpson, K. J., and M. J. Brodie. 1985. Convulsions related to enoxacin. Lancet ii:161.
34. Tsuji, A., H. Sato, Y. Kume, I. Tamai, E. Okezaki, O. Nagata, and H. Kato. 1988. Inhibitory effects of quinolone antibacterial agents on γ-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrob. Agents Chemother. 32:190-194.